Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options

Valion Bio has received unsolicited acquisition inquiries from independent third parties for Velocity Bioworks, its wholly owned biologics CDMO subsidiary, and has entered preliminary discussions while weighing a range of strategic options including a possible sale. The Board has retained a nationally recognized investment banking firm as financial advisor, with any deal's key priority being retention of production rights and manufacturing capabilities for lead candidate Entolimod. A sale could fund Entolimod's development, which is being advanced under the FDA Animal Rule as a medical countermeasure for Acute Radiation Syndrome with Fast Track and Orphan Drug designations.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.